- Home
- GLBZ vs PHGE Comparison
GLBZ vs PHGE Comparison
Compare GLBZ & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- PHGE
- Stock Information
- Founded
- GLBZ 1949
- PHGE 2015
- Country
- GLBZ United States
- PHGE Israel
- Employees
- GLBZ N/A
- PHGE N/A
- Industry
- GLBZ Major Banks
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- PHGE Health Care
- Exchange
- GLBZ Nasdaq
- PHGE Nasdaq
- Market Cap
- GLBZ 14.1M
- PHGE 13.3M
- IPO Year
- GLBZ N/A
- PHGE N/A
- Fundamental
- Price
- GLBZ $5.13
- PHGE $0.63
- Analyst Decision
- GLBZ
- PHGE Strong Buy
- Analyst Count
- GLBZ 0
- PHGE 2
- Target Price
- GLBZ N/A
- PHGE $23.00
- AVG Volume (30 Days)
- GLBZ 6.0K
- PHGE 117.4K
- Earning Date
- GLBZ 04-25-2025
- PHGE 05-19-2025
- Dividend Yield
- GLBZ 3.94%
- PHGE N/A
- EPS Growth
- GLBZ N/A
- PHGE N/A
- EPS
- GLBZ N/A
- PHGE N/A
- Revenue
- GLBZ $11,254,000.00
- PHGE N/A
- Revenue This Year
- GLBZ N/A
- PHGE N/A
- Revenue Next Year
- GLBZ N/A
- PHGE N/A
- P/E Ratio
- GLBZ N/A
- PHGE N/A
- Revenue Growth
- GLBZ N/A
- PHGE N/A
- 52 Week Low
- GLBZ $3.37
- PHGE $0.48
- 52 Week High
- GLBZ $6.99
- PHGE $4.99
- Technical
- Relative Strength Index (RSI)
- GLBZ 51.88
- PHGE 49.87
- Support Level
- GLBZ $5.07
- PHGE $0.48
- Resistance Level
- GLBZ $5.40
- PHGE $0.58
- Average True Range (ATR)
- GLBZ 0.13
- PHGE 0.06
- MACD
- GLBZ 0.00
- PHGE 0.00
- Stochastic Oscillator
- GLBZ 43.42
- PHGE 68.16
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.